JQEZ5   Click here for help

GtoPdb Ligand ID: 9332

Synonyms: EZ-005 | JQ5 | JQE5 [1]
Compound class: Synthetic organic
Comment: JQEZ5 is a potent and selective inhibitor of the histone methyltransferase EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [2-4]. A commonly identified somatic gain-of-function mutation in human EZH2 (Y646F), recapitulated in a mouse model (Y641F) induces tumourigenesis by massively redistributing repressive trimethylated Lys27 histone H3 marks, leading to altered repression and activation of polycomb-regulated loci.
JQEZ5 was developed at the Dana-Farber Cancer Institute and is openly available as a research probe.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

JQEZ5 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 112.04
Molecular weight 542.31
XLogP 5.91
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(nc2c1cnn2C(C)C)c1ccc(nc1)N1CCN(CC1)C
Isomeric SMILES CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(nc2c1cnn2C(C)C)c1ccc(nc1)N1CCN(CC1)C
InChI InChI=1S/C30H38N8O2/c1-6-7-21-14-20(4)34-30(40)24(21)17-32-29(39)23-15-26(35-28-25(23)18-33-38(28)19(2)3)22-8-9-27(31-16-22)37-12-10-36(5)11-13-37/h8-9,14-16,18-19H,6-7,10-13,17H2,1-5H3,(H,32,39)(H,34,40)
InChI Key LQTWDAYNGMMHLV-UHFFFAOYSA-N
References
1. Bradner JE, Blazar B, Flynn R, Qi J, Baker CH. (2016)
Use of compositions modulating chromatin structure for graft versus host disease (GVHD).
Patent number: WO2016073903. Assignee: Dana-Farber Cancer Institute, Inc., Regents of The University Of Minnesota. Priority date: 06/11/2015. Publication date: 12/05/2016.
2. Bradner JE, Qi J, Wong KK, Baker CH. (2016)
EZH2 inhibitors and uses thereof.
Patent number: WO2016073956. Assignee: Dana-Farber Cancer Institute, Inc. Priority date: 06/11/2015. Publication date: 12/05/2016.
3. Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J et al.. (2016)
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Nat Med, 22 (6): 632-40. [PMID:27135738]
4. Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A et al.. (2016)
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Cancer Discov, 6 (9): 1006-21. [PMID:27312177]